解讀不同指南與共識的熱點及分歧、重視肝門部膽管癌的規范化診療_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 李斌 , 張柏和 ,  姜小清

第二軍醫大學東方肝膽外科醫院膽道外科；第二軍醫大學膽道腫瘤專病診療中心（上海 200438）;

Corresponding?author：

姜小清, Email: jxq1225@sina.com

Keywords：

DOI：

10.7507/1007-9424.20160333

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李斌, 張柏和, 姜小清. 解讀不同指南與共識的熱點及分歧、重視肝門部膽管癌的規范化診療. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(11): 1293-1298. doi: 10.7507/1007-9424.20160333 Copy

1.	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
2.	赫捷, 陳萬青. 2012中國腫瘤登記年報. 軍事醫學科學出版社, 2012:64-67, 194-195.
3.	NCCN Clinical Practice Guidelines in Oncology Version. 2015. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
4.	Mansour JC, Aloia TA, Crane CH, et al. Hilar cholangiocarcinoma:expert consensus statement. HPB (Oxford), 2015, 17(8):691-699.
5.	Benavides M, Antón A, Gallego J, et al. Biliary tract cancers:SEOM clinical guidelines. Clin Transl Oncol, 2015, 17(12):982-987.
6.	European Association for the Study of the Liver. EASL Clinical Prac-tice Guidelines:Liver transplantation. J Hepatol, 2016, 64(2):433-485.
7.	Khan SA, Davidson BR, Goldin RD, et al. British Society of Gastro-enterology. Guidelines for the diagnosis and treatment of cholangio-carcinoma:an update. Gut, 2012, 61(12):1657-1669.
8.	Eckel F, Brunner T, Jelic S. ESMO Guidelines Working Group. Biliary cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2011, 22 Suppl 6:vi40-vi44.
9.	Miyazaki M, Yoshitomi H, Miyakawa S, et al. Clinical practice guidelines for the management of biliary tract cancers 2015. the 2nd English edition. J Hepatobiliary Pancreat Sci, 2015, 22(4):249-273.
10.	Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, et al. Asia-Pacific Working Group on Hepatobiliary Cancers. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol, 2013, 28(4):593-607.
11.	中國抗癌協會. 肝門部膽管癌規范化診治專家共識(2015). 中華肝膽外科雜志, 2015, 21(8):505-511.
12.	中華醫學會外科學分會膽道外科學組, 解放軍全軍肝膽外科專業委員會. 肝門部膽管癌診斷和治療指南(2013版). 中華外科雜志, 2013, 51(10):865-871.
13.	Charbel H, Al-Kawas FH. Cholangiocarcinoma:epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep, 2011, 3(2):182-187.
14.	Chen P, Li B, Zhu Y, et al. Establishment and validation of a progno-stic nomogram for patients with resectable perihilar cholangiocar-cinoma. Oncotarget, 2016, 7(24):37319-37330.
15.	Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg, 1992, 15(1):31-38.
16.	Gazzaniga GM, Faggioni A, Filauro M. Surgical treatment of proximal bile duct tumors. Int Surg, 1985, 70(1):45-48.
17.	Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 25 patients with hilar cholangiocarcinoma. Ann Surg, 2001, 34(4):507-517.
18.	American Joint Committee on Cancer. UICC/AJCC stage grouping. 7th edition. 2009. http://www.cancerstaging.org.
19.	Deoliveira ML, Schulick RD, Nimura Y, et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology, 2011, 53(4):1363-1371.
20.	Chaiteerakij R, Harmsen WS, Marrero CR, et al. A new clinically based staging system for perihilar cholangiocarcinoma. Am J Gastroenterol, 2014, 109(12):1881-1890.
21.	Kawashima H, Itoh A, Ohno E, et al. Preoperative endoscopic naso-biliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma:a retrospective study of efficacy and risk factors related to complications. Ann Surg, 2013, 257(1):121-127.
22.	姜小清, 易濱, 吳孟超, 等. 肝門部膽管癌10年外科治療經驗. 中華消化外科雜志, 2010, 9(3):180-182.
23.	易濱, 姜小清. 肝門部膽管癌的計劃性肝切除. 中國普外基礎與臨床雜志, 2011, 18(6):576-578.
24.	張蜀豫, 馬興濤, 姜小清, 等. 肝門部膽管癌患者術前口服膽汁的療效研究. 腫瘤代謝與營養電子雜志, 2015, 2(2):48-51.
25.	Friman S, Foss A, Isoniemi H, et al. Liver transplantation for cholan-giocarcinoma:selection is essential for acceptable results. Scand J Gastroenterol, 2011, 46(3):370-375.
26.	Croome KP, Rosen CB, Heimbach JK, et al. Is liver transplantation appropriate for patients with potentially resectable de novo hilar cholangiocarcinoma? J Am Coll Surg, 2015, 221(1):130-139.
27.	Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys, 2000, 46(3):581-587.
28.	Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer:improved survival after photodynamic therapy. Am J Gastroenterol, 2005, 100(11):2426-2430.
29.	Cheon YK, Cho YD, Baek SH, et al. Comparison of survival of advanced hilar cholangiocarcinoma after biliary drainage alone versus photodynamic therapy with external drainage. Korean J Gastroenterol, 2004, 44(5):280-287.

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
2. 赫捷, 陳萬青. 2012中國腫瘤登記年報. 軍事醫學科學出版社, 2012:64-67, 194-195.
3. NCCN Clinical Practice Guidelines in Oncology Version. 2015. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
4. Mansour JC, Aloia TA, Crane CH, et al. Hilar cholangiocarcinoma:expert consensus statement. HPB (Oxford), 2015, 17(8):691-699.
5. Benavides M, Antón A, Gallego J, et al. Biliary tract cancers:SEOM clinical guidelines. Clin Transl Oncol, 2015, 17(12):982-987.
6. European Association for the Study of the Liver. EASL Clinical Prac-tice Guidelines:Liver transplantation. J Hepatol, 2016, 64(2):433-485.
7. Khan SA, Davidson BR, Goldin RD, et al. British Society of Gastro-enterology. Guidelines for the diagnosis and treatment of cholangio-carcinoma:an update. Gut, 2012, 61(12):1657-1669.
8. Eckel F, Brunner T, Jelic S. ESMO Guidelines Working Group. Biliary cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2011, 22 Suppl 6:vi40-vi44.
9. Miyazaki M, Yoshitomi H, Miyakawa S, et al. Clinical practice guidelines for the management of biliary tract cancers 2015. the 2nd English edition. J Hepatobiliary Pancreat Sci, 2015, 22(4):249-273.
10. Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, et al. Asia-Pacific Working Group on Hepatobiliary Cancers. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol, 2013, 28(4):593-607.
11. 中國抗癌協會. 肝門部膽管癌規范化診治專家共識(2015). 中華肝膽外科雜志, 2015, 21(8):505-511.
12. 中華醫學會外科學分會膽道外科學組, 解放軍全軍肝膽外科專業委員會. 肝門部膽管癌診斷和治療指南(2013版). 中華外科雜志, 2013, 51(10):865-871.
13. Charbel H, Al-Kawas FH. Cholangiocarcinoma:epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep, 2011, 3(2):182-187.
14. Chen P, Li B, Zhu Y, et al. Establishment and validation of a progno-stic nomogram for patients with resectable perihilar cholangiocar-cinoma. Oncotarget, 2016, 7(24):37319-37330.
15. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg, 1992, 15(1):31-38.
16. Gazzaniga GM, Faggioni A, Filauro M. Surgical treatment of proximal bile duct tumors. Int Surg, 1985, 70(1):45-48.
17. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 25 patients with hilar cholangiocarcinoma. Ann Surg, 2001, 34(4):507-517.
18. American Joint Committee on Cancer. UICC/AJCC stage grouping. 7th edition. 2009. http://www.cancerstaging.org.
19. Deoliveira ML, Schulick RD, Nimura Y, et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology, 2011, 53(4):1363-1371.
20. Chaiteerakij R, Harmsen WS, Marrero CR, et al. A new clinically based staging system for perihilar cholangiocarcinoma. Am J Gastroenterol, 2014, 109(12):1881-1890.
21. Kawashima H, Itoh A, Ohno E, et al. Preoperative endoscopic naso-biliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma:a retrospective study of efficacy and risk factors related to complications. Ann Surg, 2013, 257(1):121-127.
22. 姜小清, 易濱, 吳孟超, 等. 肝門部膽管癌10年外科治療經驗. 中華消化外科雜志, 2010, 9(3):180-182.
23. 易濱, 姜小清. 肝門部膽管癌的計劃性肝切除. 中國普外基礎與臨床雜志, 2011, 18(6):576-578.
24. 張蜀豫, 馬興濤, 姜小清, 等. 肝門部膽管癌患者術前口服膽汁的療效研究. 腫瘤代謝與營養電子雜志, 2015, 2(2):48-51.
25. Friman S, Foss A, Isoniemi H, et al. Liver transplantation for cholan-giocarcinoma:selection is essential for acceptable results. Scand J Gastroenterol, 2011, 46(3):370-375.
26. Croome KP, Rosen CB, Heimbach JK, et al. Is liver transplantation appropriate for patients with potentially resectable de novo hilar cholangiocarcinoma? J Am Coll Surg, 2015, 221(1):130-139.
27. Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys, 2000, 46(3):581-587.
28. Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer:improved survival after photodynamic therapy. Am J Gastroenterol, 2005, 100(11):2426-2430.
29. Cheon YK, Cho YD, Baek SH, et al. Comparison of survival of advanced hilar cholangiocarcinoma after biliary drainage alone versus photodynamic therapy with external drainage. Korean J Gastroenterol, 2004, 44(5):280-287.

Previous Article
聯合計劃性肝切除治療肝門部膽管癌的理論與實踐
Next Article
肝門部膽管癌根治性切除的可能性評估

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

解讀不同指南與共識的熱點及分歧、重視肝門部膽管癌的規范化診療

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content